Leonid Timashev
Stock Analyst at RBC Capital
(1.14)
# 3,548
Out of 4,873 analysts
85
Total ratings
31.17%
Success rate
-13.32%
Average return
Main Sectors:
Stocks Rated by Leonid Timashev
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRMD CorMedix | Reiterates: Outperform | $13 → $17 | $15.72 | +8.14% | 1 | Jun 20, 2025 | |
| ADCT ADC Therapeutics | Maintains: Outperform | $8 → $5 | $2.86 | +74.83% | 1 | Jun 20, 2025 | |
| NUVB Nuvation Bio | Maintains: Outperform | $10 → $6 | $2.05 | +193.40% | 1 | Jun 17, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Outperform | $193 → $186 | $104.35 | +78.25% | 11 | Jun 12, 2025 | |
| INSM Insmed | Maintains: Outperform | $99 → $106 | $105.88 | +0.11% | 3 | Jun 11, 2025 | |
| EWTX Edgewise Therapeutics | Reiterates: Outperform | $48 | $14.74 | +225.64% | 12 | Jun 5, 2025 | |
| CATX Perspective Therapeutics | Maintains: Outperform | $15 → $16 | $3.82 | +318.85% | 1 | Jun 3, 2025 | |
| BHVN Biohaven | Downgrades: Sector Perform | $54 → $21 | $14.71 | +42.76% | 12 | May 19, 2025 | |
| CYTK Cytokinetics | Maintains: Outperform | $82 → $80 | $33.39 | +139.59% | 3 | May 7, 2025 | |
| ALKS Alkermes | Maintains: Sector Perform | $39 → $40 | $29.35 | +36.29% | 2 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $8 | $1.29 | +522.57% | 6 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $3 | $1.35 | +123.05% | 1 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $40 | $18.46 | +116.68% | 6 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $70 | $69.01 | +1.44% | 1 | Jan 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $18 | $2.53 | +611.46% | 4 | Jan 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $86 | $34.38 | +150.18% | 12 | Dec 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $4 | $3.96 | +1.01% | 8 | Aug 6, 2024 |
CorMedix
Jun 20, 2025
Reiterates: Outperform
Price Target: $13 → $17
Current: $15.72
Upside: +8.14%
ADC Therapeutics
Jun 20, 2025
Maintains: Outperform
Price Target: $8 → $5
Current: $2.86
Upside: +74.83%
Nuvation Bio
Jun 17, 2025
Maintains: Outperform
Price Target: $10 → $6
Current: $2.05
Upside: +193.40%
Axsome Therapeutics
Jun 12, 2025
Maintains: Outperform
Price Target: $193 → $186
Current: $104.35
Upside: +78.25%
Insmed
Jun 11, 2025
Maintains: Outperform
Price Target: $99 → $106
Current: $105.88
Upside: +0.11%
Edgewise Therapeutics
Jun 5, 2025
Reiterates: Outperform
Price Target: $48
Current: $14.74
Upside: +225.64%
Perspective Therapeutics
Jun 3, 2025
Maintains: Outperform
Price Target: $15 → $16
Current: $3.82
Upside: +318.85%
Biohaven
May 19, 2025
Downgrades: Sector Perform
Price Target: $54 → $21
Current: $14.71
Upside: +42.76%
Cytokinetics
May 7, 2025
Maintains: Outperform
Price Target: $82 → $80
Current: $33.39
Upside: +139.59%
Alkermes
May 2, 2025
Maintains: Sector Perform
Price Target: $39 → $40
Current: $29.35
Upside: +36.29%
Mar 19, 2025
Reiterates: Outperform
Price Target: $8
Current: $1.29
Upside: +522.57%
Mar 19, 2025
Maintains: Buy
Price Target: $3
Current: $1.35
Upside: +123.05%
Jan 24, 2025
Reiterates: Outperform
Price Target: $40
Current: $18.46
Upside: +116.68%
Jan 23, 2025
Reiterates: Sector Perform
Price Target: $70
Current: $69.01
Upside: +1.44%
Jan 15, 2025
Reiterates: Outperform
Price Target: $18
Current: $2.53
Upside: +611.46%
Dec 9, 2024
Reiterates: Outperform
Price Target: $86
Current: $34.38
Upside: +150.18%
Aug 6, 2024
Reiterates: Sector Perform
Price Target: $4
Current: $3.96
Upside: +1.01%